Our approach eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment and inducing a tumor-specific immune response by in situ vaccination.
There is no need for pre-treatment sequencing.
CyPep-1 has strong single agent activity
and synergizes with checkpoint inhibitors.
Watch the animation to learn more about how our technology works.
TIP! Mouse-over the numbered hotspots for more information
1. LOCAL
After releasing antigens CyPep-1 eliminates cancer cells by inducing rapid lytic cell death.
2. SYSTEMIC
Tumor-specific immune activation.
The immune system recognizes tumor cells, even when they have not been treated with CyPep-1.
3. COMBINED
Tumor-cell death.
CyPep-1 is highly synergistic with checkpoint inhibitors, even in cold tumors.